Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$36.71 USD
+0.29 (0.80%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $36.73 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$36.71 USD
+0.29 (0.80%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $36.73 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Zacks News
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Collegium Pharmaceutical (COLL) Q2 Earnings Miss Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -90.08% and 0.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of -26.67% and 12.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?
by Zacks Equity Research
Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.
Collegium Pharmaceutical (COLL) Lags Q1 Earnings Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -38.14% and 6.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer (PFE), BioNTech (BNTX) COVID Booster Effective in Young Kids
by Zacks Equity Research
A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.
Merck's (MRK) Pneumococcal Jab Gets FDA's Breakthrough Tag
by Zacks Equity Research
The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.
INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate
by Zacks Equity Research
INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.
Actinium (ATNM) Up on Commercialization Deal With Immedica
by Zacks Equity Research
Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.
Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines
by Zacks Equity Research
Matinas BioPharma (MTNB) forms an exclusive partnership with BioNTech (BNTX) to develop and advance novel formulations for mRNA vaccines.
FDA Finds Deficiencies in Myovant (MYOV), Pfizer's Myfembree sNDA
by Zacks Equity Research
Though the FDA identified deficiencies in Myovant's (MYOV) Myfembree sNDA for managing endometriosis-associated pain, a final decision on the application is yet to be communicated.
Aerie (AERI) Expands Market Presence Despite Stiff Competition
by Zacks Equity Research
Aerie (AERI) is progressing well with the development of its ophthalmology pipeline. Its partnership with Santen Pharmaceuticals allows it to expand the presence of its drugs outside the United States.
4 Reasons to Add Novo Nordisk (NVO) Stock to Your Portfolio
by Zacks Equity Research
Novo Nordisk's (NVO) portfolio of marketed drugs are driving year over year growth. The company has one of the broadest diabetes portfolios in the industry.
BioCryst (BCRX) Pauses Enrolment in Key Studies, Stock Down
by Zacks Equity Research
BCX9930 is a BioCryst Pharmaceuticals' (BCRX) oral Factor D inhibitor being evaluated in several studies for the treatment of complement-mediated diseases
JAZZ Inks Deal With Werewolf to Add Oncology Candidate
by Zacks Equity Research
Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.
Pfizer (PFE) to Boost RSV Portfolio With ReViral Acquisition
by Zacks Equity Research
Pfizer (PFE) inks an agreement to acquire ReViral for up to $525 million, which will add the latter's respiratory syncytial virus therapeutic candidates to its portfolio.
bluebird (BLUE) Undertakes Restructuring Moves to Curb Cash Burn
by Zacks Equity Research
bluebird (BLUE) intends to reduce the existing workforce by nearly 30% to reduce 2022 operating expenses by 35-40%. This is likely to generate cost savings of $160 million over two years.
Novartis (NVS) Gets FDA Nod for Vijoice in Rare Disorder
by Zacks Equity Research
The FDA approves Novartis' (NVS) Vijoice (alpelisib) for the treatment of select patients with PIK3CA-related overgrowth spectrum.
COLL or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
Corcept (CORT) Completes Enrolment in Mid-Stage Weight Gain Study
by Zacks Equity Research
Corcept (CORT) completes enrolling patients in a phase II study on miricorilant for treating recent antipsychotic-induced weight gain. Data from this study is expected in fourth-quarter 2021.
Theravance's (TBPH) Hypotension Study Misses Primary Goal
by Zacks Equity Research
Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic nOH fails to meet its goal. The study benefitted patients with a rare neurodegenerative disorder.
IGM (IGMS) Skyrockets on Collaboration Deal With Sanofi
by Zacks Equity Research
IGM Biosciences (IGMS) inks a deal with Sanofi (SNY) to discover and develop new therapies based on its proprietary technology, which is set to target oncology, immunology and inflammation targets.